Caplin Point climbs 7% as subsidiary gets US FDA nod for anesthetic drug
Ropivacaine Hydrochloride is a long acting local anesthetic drug used for surgery or acute pain management.13-04-2020
13-04-2020
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release- Disclosure under Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements)Regulations,2015.13-04-2020
CAPLIN POINT LABORATORIES LTD. - 524742 - Clarification
With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded, Caplin Point Laboratories Ltd has submitted to BSE a Clarification as under:"All the material information's and announcements that may have bearing on the operations/performance of the Company which include all the necessary disclosures are in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)Regulations,2015, and under Insider Trading Regulations have been disclosed to the respective Stock Exchanges under the prescribed timeline. There is no pending information or announcement to be disclosed by the Company which may have a bearing on the price movements of the shares of the Company. The price movements of the shares of the Company is purely due to market conditions and market driven and the Company is in no way connected to such price movements."04-04-2020
CAPLIN POINT LABORATORIES LTD. - 524742 - Clarification sought from Caplin Point Laboratories Ltd
The Exchange has sought clarification from Caplin Point Laboratories Ltd on April 03rd, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.03-04-2020
CAPLIN POINT LABORATORIES LTD. - 524742 - Closure of Trading Window
Closure of Trading Window31-03-2020
Caplin Steriles gets US FDA nod for Verapamil Hydrochloride injection
Shares up nearly 20 per cent26-03-2020
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor Call26-03-2020
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release -Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.26-03-2020
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate17-03-2020
Caplin Point Laboratories Ltd - 524742 - Board declares Interim Dividend
Caplin Point Laboratories Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on March 04, 2020, inter alia, have approved the payment of Interim Dividend of Rs. 2.10 paise (105%) per equity share of Rs. 2/- each for the financial year 2019-2020.Interim Dividend will be paid to the shareholders on or before March 25, 2020.04-03-2020